Aurinia Pharmaceuticals (AUPH) Current Deferred Revenue (2017 - 2026)

Aurinia Pharmaceuticals (AUPH) has 10 years of Current Deferred Revenue data on file, last reported at $5.0 million in Q1 2026.

• Quarterly Current Deferred Revenue rose 9.62% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (up 9.62% YoY) and the FY2025 annual result came in at $3.7 million, down 66.19% from the prior year.
• Current Deferred Revenue improved to $5.0 million in Q1 2026, from $3.7 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $11.0 million in Q4 2024 to a low of $3.1 million in Q4 2022.
• A 5-year average of $4.8 million and a median of $4.6 million in 2025 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue soared 1556.84% — and 2025, when it sank 66.19%.
• Tracing AUPH's Current Deferred Revenue over 5 years: stood at $3.1 million in 2022, then soared by 52.89% to $4.8 million in 2023, then jumped by 128.59% to $11.0 million in 2024, then slumped by 66.19% to $3.7 million in 2025, then soared by 35.38% to $5.0 million in 2026.
• The last three Current Deferred Revenue figures came in at $5.0 million (Q1 2026), $3.7 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.